Drug intelligence / Profile preview

PMS-101

Development stage: Phase 2
Lead developer: PRIMORIS Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

PMS-101 is an investigational exosome-based therapy developed by Primoris Therapeutics. It is currently in early clinical development for the treatment of burns, specifically mid-dermal burns. The mechanism of action for PMS-101 has not been disclosed or remains unknown at this time. Clinical trials are ongoing to evaluate its safety, tolerability, and efficacy compared to standard-of-care treatments in patients with burn injuries.

Beyond the preview

Go deeper on PMS-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMS-101.

Explore the full profile